Severe infections related to treatment are common in patients with multiple myeloma (MM). Genetic polymorphisms of the immune system may influence the risk of infections. Mannan-binding lectin (MBL) is part of the innate immune system, and individuals homozygous for wild-type MBL encoding gene (MBL2) have a wellfunctioning MBL pathway of complement activation, in contrast to individuals carrying one or two variant alleles. We evaluated 113 courses of high-dose melphalan and autologous stem cell transplantation (ASCT) in patients with MM. Patients homozygous for wild-type MBL2 had a significantly reduced risk of septicaemia during the ASCT procedure compared with patients carrying variant MBL2: Odds Ratio (OR) 0.19 (95% CI: 0.04-0.77), (P ¼ 0.02) in multivariate analysis. The risk of Common Toxicity Criteria grade 3-4 infections in general was not affected by wild-type MBL2: OR 1.20 (95% CI: 0.52-2.78), (P ¼ 0.67). The findings indicate that MBL to some extent protects against the most severe infections during ASCT.
Introduction
Patients suffering from multiple myeloma (MM) are at a high risk of infections. The disease itself often compromises several modalities of the immune defence, most apparently the production of polyclonal antibodies, T-cell functions and bone marrow function. [1] [2] [3] Morbidity and mortality due to infections during chemotherapy, adding further immunosuppression, are significant. [4] [5] [6] High-dose melphalan and autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with MM. 7, 8 Infections are very common during this treatment: up to 80% of patients have fever, and more than one third suffer from well-defined infections. [9] [10] [11] These numbers are based on quite small series of patients. A closer description of infectious toxicity is not seen in the large prospective trials of ASCT. 7, 8, 12 In one study, however, more than half of the patients suffered from grade 2-4 infections during ASCT. 8 The mannan-binding lectin (MBL) pathway of the complement system is part of the innate immune system and seems to influence the risk of infections in cancer patients during treatment (further described later). MBL is produced by hepatocytes and is found in the circulation as oligomers of identical polypeptide chains. Binding of the carbohydrate recognizing regions of the MBL oligomers to specific carbohydrate patterns on the surface of microbes initiates an activation process, as described in detail in a number of reviews. [13] [14] [15] The activation process leads to complement activation with formation of the membrane attack complex, possible subsequent lysis of microbes and formation of split products acting as opsonins, as well as the generation of chemotactic and cell activating anaphylatoxins. The serum level and function of the MBL oligomers are strongly influenced by genetic polymorphism. In particular, common variants in the gene encoding MBL are important. The gene is termed MBL2 and is located in the chromosome region 10q11.1-q21. 16 The wild-type allele is termed A. Three different single nucleotide polymorphisms (SNPs), responsible for exchange of amino acids in the collagen-like part of the molecule, are termed B (G54D), C (G57E), and D (R52C). Collectively the variants are termed 'O', and they are associated with reduced levels of functional MBL in serum. Also common variants of the promotor region of the gene influence the MBL levels. Especially the promotor, variant 'LXP', a combination of three mutations located at position À550 (H/L variants), À221 (Y/X variants) and þ 4 (P/Q variants), is associated with a reduced level of MBL in serum. The complete genotype LXPA/LXPA is, although homozygous for wildtype MBL2, often associated with low levels and function of MBL.
The impact of the MBL system on the occurrence of chemotherapy-related infections in malignant diseases has been studied by several scientists. The conclusions have, however, differed. Neth et al. 19 found a clear correlation between wild-type MBL2 and a decreased risk and duration of neutropenic fever. Peterslund et al. 20 found that patients with clinically significant infections after chemotherapy had significantly lower levels of MBL in serum, but later studies have been partly contradictory. Bergmann et al. 21 found no indications of a protective effect of a high-serum MBL in patients with acute myeloid leukaemia (AML), and Kilpatrick et al. 22 found only a weak association between low serum MBL and infections. In the latter study all infections, contracted in a study group of mixed haematological malignancies, were divided into four categories, and only the most severe category of infections was significantly more common in patients with low serum MBL. 22 We recently found indications of a reduced risk of septicaemia in MM with wild-type MBL2 during induction chemotherapy. 23 Only one study, in a series of mixed malignancies, addressed the risk of infections in ASCT. The results indicated that highfunctioning MBL genes decrease the risk of major bacterial infections. 24 Only one of the earlier published studies was made on a uniform group of patients, namely patients with AML, 21 and new studies on the topic should probably relate to specific patient groups. In this study, we focus on the impact of MBL2 polymorphism on the risk of severe infections related to ASCT in patients with MM.
Patients and methods
We retrospectively analysed 113 consecutive treatment courses by using patient records and database extractions of microbiological and biochemical data for identification and characterization of severe infections. Most patients (n ¼ 104) were newly diagnosed and received ASCT as consolidation after standard induction therapy: vincristine/ doxorubicine/dexamethasone (VAD) or cyclophosphamide/dexamethasone. These patients have also been considered elsewhere in a study of the induction therapy in 133 newly diagnosed MM patients. 23 Five other patients were also newly diagnosed, but had had other induction regimens, typically cyclophosphamide in nonstandard dosages. Four patients were not newly diagnosed and had had various first-line treatments. Before ASCT, they had been treated for progression of MM, typically with VAD, and had ASCT as consolidation therapy. Only first time ASCT courses were included in this study, and none of the patients were treated with renal dialysis during ASCT.
One person (IM) blinded to the genotypes reviewed the patient data. Strict diagnostic criteria for infections were used. In addition to clinical observations, septicaemia was culture positive, pneumonia was chest X-ray positive, and neutropenic fever was defined as fever X38.51C together with a neutrophil count p0.5 Â 10 9 /l, without documented focus or microbial agent. Intravenous catheter-related infection was recorded as either due to: (1) significant clinical signs (redness, pus, swelling or pain) in relation to the catheter site together with positive culture from the insertion site of the catheter or, (2) if blood cultures from the catheter or culture of the tip of the catheter after removal were positive, together with clinical signs. The observation period started from the time of administration of high-dose melphalan and ended at discharge from the department. A second observation period was made from discharge until day 180 after ASCT.
The series of patients was treated in a single institution during the period 1994-2003. The conditioning treatment was melphalan 200 mg/m 2 in 112 patients. One patient received 140 mg/m 2 because of elevated serum-creatinine. The autograft used in most patients (n ¼ 112) was unmanipulated peripheral stem cells, harvested after mobilization with high-dose cyclophosphamide and G-CSF. One patient had an autograft from a bone marrow aspiration. The ASCT regimen was very standardized. Prophylactic measures included isolation in high-pressure rooms with air filters, until the second day with a neutrophil count X0.5 Â 10 9 /l. In addition, the patients received oral ciprofloxacin, 250 mg twice daily; oral fluconazole, 100 mg daily; oral aciclovir, 400 mg three times daily (in 112 patients) from day -3; and G-CSF, 300 mg day from day þ 4 after reinfusion of stem cells (day 0). Antibiotics and growth factor were given, until isolation was abandoned. In cases of severe nausea, oral antibiotics were substituted by intravenous administration in equivalent doses. Polyclonal immunoglobulins were not given to any of the patients.
Breakthrough fever, X38.51C, was always treated with intravenous vancomycin and ceftazidime after a clinical examination and sampling of blood cultures. Prophylactic oral antibiotics were not discontinued, if breakthrough fever occurred. One of the patients received amphotericin B, as treatment for suspected fungal infection, but the diagnosis was not confirmed.
Biochemical and microbiological data were identified in the databases at the Departments of Biochemistry and Microbiology, respectively. Quantitation of hypogammaglobulinaemia was carried out by counting the number of affected immunoglobulin (Ig) classes. 25 Patients were subdivided into two categories: patients with 0 or 1 affected Ig class, and patients with two or three affected Ig classes in serum. The presence of an M-protein was always interpreted as an indication of the particular Ig class because of the difficulty of quantitating polyclonal antibodies of the same Ig class as the M-protein.
Disease status, that is response to the induction chemotherapy given before ASCT, was determined according to criteria used by the Nordic Myeloma Study Group. 7 The patients were genotyped by using samples of stem cells routinely stored in a tissue bank after apheresis or bone marrow harvest. Genomic DNA was extracted from 200 ml of peripheral or bone marrow stem cells using the QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). Multiplex real-time polymerase chain reaction (PCR) was used to genotype for polymorphisms at codons 52, 54 and 57 in exon 1 of MBL2. 26 A new genotyping method, based on the 5 0 nuclease (TaqMan) assay in combination with minor-groove-binder (MGB) probes, was used for screening for the promotor polymorphisms. A variant of this method was previously used by others to discriminate alleles of MBL2.
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Statistical analyses were made with the STATA software (Statacorp, USA) using w 2 , Fisher's exact or MannWhitney's test, when appropriate. In addition, multiple logistic regression analyses were made by using breakthrough fever (yes/no) and septicemia (yes/no) as dependent variables.
Two models were made. One model included MBL2-subgroup, gender, disease status after induction therapy, immune status, age, and serum creatinine as independent variables in the analysis of breakthrough fever. As a result of the lower number of septicaemias, another model was made for analysis of this outcome by using MBL2-subgroup and disease status after induction therapy as independent variables.
Results
The patients were divided into two subgroups: patients homozygous (AA) for wild-type MBL2 (n ¼ 72) and other patients, AO/OO, (n ¼ 41) including 40 heterozygous individuals and one individual homozygous for variant MBL2. There was an uneven distribution of gender and subtype of myeloma between the two groups, but otherwise the groups were comparable (Table 1) .
In Table 2 aspects of infections during ASCT are shown. Breakthrough fever was common (63%) and evenly distributed between the two subgroups, but there was a trend towards difference in the occurrence of septicaemia between the variant and wild-type MBL2 groups (17 versus 6% of patients, respectively). Inversely, neutropenic fever without proven focus or microbial agent was more common in the wild-type MBL2 group (43 versus 27% of patients). Thus, there were more very severe infections occurring in the variant MBL2 group, where also the two /kg body weight; n ¼ 112.
MBL2 and infections after ASCT in myeloma patients I Mlle et al lethal infections were seen. The differences were, however, not significantly different in univariate statistical analyses. In Table 2 details concerning neutrophil recovery are shown. The median number of CD34-positive cells reinfused (assessed in 112 patients) was slightly lower in the variant MBL2 group compared with the wild-type MBL2 group. The difference, however, was not significant, and the number of days until neutrophil recovery was equal in the two subgroups.
In multivariate analyses wild-type MBL2 was not associated with risk of breakthrough fever (Table 3a) , but significantly (Po0.02) associated with a reduced risk of septicaemia (Table 3b) .
Data were reanalysed referring the individuals with the LXPA/LXPA genotype (n ¼ 10) to the variant MBL2 group. Data for these additional analyses are not shown in detail, but the risk of septicaemia in wild-type MBL2 (Table 3b ) slightly increased after this adjustment: odds ratio (OR) ¼ 0.25, (95% CI: 0.06-1.03) (P ¼ 0.06). The results do not definitely clarify whether the individuals carrying LXPA/LXPA should be considered MBL sufficient or not. The number of these patients is too small for a firm conclusion.
Severe infections were much rarer after discharge and until day 180 (Table 4) , and no association with MBL2 was seen for this period. Thirty patients had a shorter follow-up than scheduled. Of these, two patients died of progression of MM and eight other patients were treated with oral melphalan and prednisolone for progression. The rest returned as outpatients to a local haematological department and were lost to further follow-up. Only two out of 15 grade 3-4 four infections were seen in the relapsed patients.
Discussion
In this study of myeloma patients treated with ASCT, we found indications of a protective effect of wild-type MBL2 against documented septicaemia, but not against breakthrough fever in general.
Our study group is homogenous, and even though the data are retrospective, we consider them to be of good quality, due to the meticulous monitoring of the patients during ASCT. There are some considerations to be made, however. Breakthrough fever, covering all CTC grade 3-4 infections, was used as a clinical endpoint because documented fever above 38.51C always leads to clinical evaluation, blood sampling for culture, and treatment with antibiotics as described previously. Although by definition a grade 3 infection using the Common Toxicity Criteria, 28 we do not consider neutropenic fever above 38.51C without proven focus or agent to be a verified infection. However, septicaemia is easily documented in our material, which does not contain episodes with growth of skin bacteria in blood cultures. In addition, septicaemia is by far the most serious infection seen in this study and is therefore a reasonable end point. We used strict criteria for the diagnosis of pneumonia, and this diagnosis may be underestimated, since not every febrile patient had a chest X-ray performed. If there is no clinical suspicion, we often refrain from this examination, which temporarily violates the isolation regimen. Owing to these considerations, we believe that assumptions of the risk of pneumonia and associations with MBL genotypes should not be made from the present study.
We do not routinely score the patients for the severity of mucositis. In our experience, it is nearly always severe after conditioning with high-dose melphalan, but we are not able to compare the two groups in this respect. Severe mucositis may be a risk factor for infection, and monitoring of mucositis would be relevant in a prospective study.
The distribution of the M-protein variants differs between the two groups of patients. We have no explantion for this, but do not consider the type of M-protein to be a risk factor for infections.
Although not significantly, the number of reinfused CD34-positive cells was slightly lower in the variant versus the wild-type MBL2 group. This, however, did not influence the neutrophil recovery time.
Only one other study so far described, the occurrence of infections in ASCT related to MBL2 polymorphisms. Horiuchi et al. 24 found that the low producing genotypes B/B and B/A were associated with a highly increased and significant risk of major bacterial infections in a series of patients with mixed malignancies. In 113 patients, they found a much lower occurrence of bacterial infections (n ¼ 10) than we did (n ¼ 29, documented pneumonia The relation between MBL2 polymorphisms and the function of the MBL system is complex, as significant variation between serum levels is seen within each genotype, 17, 18 and the association found in the present study might be stronger, if serum levels of MBL are measured as well. This was seen in a recent study of septicaemia in nonimmunosuppressed intensive care patients, where variant MBL2 was associated with an increased risk of severe sepsis and septic shock, but not associated with mortality. In contrast plasma MBL o1000 mg/l was associated with increased mortality. 29 The major advantage of genotyping of patients is the consistency of this analysis as a risk marker. However, since the ability to elevate or maintain the serum level of MBL during severe infection possibly improves the outcome, 29 it may be useful in the individual patient to study the kinetics of MBL oligomers during severe infection. 29 In conclusion, we found, in multivariate analysis, a decreased risk of septicaemia during ASCT in MM patients with wild-type MBL2. The finding suggests a protective effect of MBL against blood stream infections in these extremely immunosuppressed patients. The results could lead to considerations of increased antibiotic prophylaxis or to future MBL replacement trials in MBL deficient patients with MM.
